Intrinsic value of NuVasive - NUVA

Previous Close

$64.06

  Intrinsic Value

$66.59

stock screener

  Rating & Target

hold

+4%

  Value-price divergence*

+639%

Previous close

$64.06

 
Intrinsic value

$66.59

 
Up/down potential

+4%

 
Rating

hold

 
Value-price divergence*

+639%

*Intrinsic value change (in %) minus stock price change (in %) in the past 12 months.

We calculate the intrinsic value of NUVA stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2016), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 3.2

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2016(a)
   2017
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  18.62
  16.30
  15.17
  14.15
  13.24
  12.41
  11.67
  11.01
  10.40
  9.86
  9.38
  8.94
  8.55
  8.19
  7.87
  7.59
  7.33
  7.09
  6.88
  6.70
  6.53
  6.37
  6.24
  6.11
  6.00
  5.90
  5.81
  5.73
  5.66
  5.59
  5.53
Revenue, $m
  962
  1,119
  1,289
  1,471
  1,666
  1,872
  2,091
  2,321
  2,563
  2,815
  3,079
  3,355
  3,641
  3,940
  4,250
  4,572
  4,907
  5,255
  5,617
  5,993
  6,384
  6,791
  7,215
  7,656
  8,115
  8,594
  9,093
  9,614
  10,158
  10,726
  11,320
Variable operating expenses, $m
 
  918
  1,050
  1,192
  1,344
  1,504
  1,674
  1,853
  2,041
  2,237
  2,443
  2,608
  2,831
  3,063
  3,304
  3,555
  3,815
  4,086
  4,367
  4,659
  4,964
  5,280
  5,609
  5,952
  6,309
  6,682
  7,070
  7,475
  7,898
  8,340
  8,801
Fixed operating expenses, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  839
  918
  1,050
  1,192
  1,344
  1,504
  1,674
  1,853
  2,041
  2,237
  2,443
  2,608
  2,831
  3,063
  3,304
  3,555
  3,815
  4,086
  4,367
  4,659
  4,964
  5,280
  5,609
  5,952
  6,309
  6,682
  7,070
  7,475
  7,898
  8,340
  8,801
Operating income, $m
  124
  200
  238
  279
  322
  368
  417
  468
  522
  578
  637
  746
  810
  877
  946
  1,017
  1,092
  1,169
  1,250
  1,334
  1,421
  1,511
  1,605
  1,704
  1,806
  1,912
  2,023
  2,139
  2,260
  2,387
  2,519
EBITDA, $m
  227
  281
  324
  370
  419
  471
  526
  584
  645
  708
  775
  844
  916
  991
  1,069
  1,150
  1,234
  1,322
  1,413
  1,507
  1,606
  1,708
  1,815
  1,926
  2,041
  2,162
  2,287
  2,418
  2,555
  2,698
  2,847
Interest expense (income), $m
  13
  20
  24
  29
  35
  41
  47
  53
  60
  67
  75
  82
  91
  99
  108
  117
  127
  136
  147
  157
  169
  180
  192
  205
  218
  231
  246
  260
  276
  292
  309
Earnings before tax, $m
  65
  181
  214
  249
  287
  328
  370
  415
  462
  511
  562
  664
  720
  778
  838
  900
  965
  1,033
  1,103
  1,176
  1,252
  1,331
  1,413
  1,499
  1,588
  1,681
  1,778
  1,879
  1,985
  2,095
  2,210
Tax expense, $m
  30
  49
  58
  67
  78
  88
  100
  112
  125
  138
  152
  179
  194
  210
  226
  243
  261
  279
  298
  318
  338
  359
  382
  405
  429
  454
  480
  507
  536
  566
  597
Net income, $m
  37
  132
  156
  182
  210
  239
  270
  303
  337
  373
  410
  485
  525
  568
  612
  657
  705
  754
  805
  859
  914
  972
  1,032
  1,094
  1,159
  1,227
  1,298
  1,372
  1,449
  1,529
  1,613

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  154
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  1,571
  1,648
  1,898
  2,166
  2,453
  2,758
  3,079
  3,418
  3,774
  4,146
  4,535
  4,941
  5,363
  5,802
  6,259
  6,734
  7,227
  7,740
  8,272
  8,826
  9,402
  10,002
  10,625
  11,275
  11,952
  12,657
  13,392
  14,160
  14,961
  15,797
  16,671
Adjusted assets (=assets-cash), $m
  1,417
  1,648
  1,898
  2,166
  2,453
  2,758
  3,079
  3,418
  3,774
  4,146
  4,535
  4,941
  5,363
  5,802
  6,259
  6,734
  7,227
  7,740
  8,272
  8,826
  9,402
  10,002
  10,625
  11,275
  11,952
  12,657
  13,392
  14,160
  14,961
  15,797
  16,671
Revenue / Adjusted assets
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
Average production assets, $m
  279
  324
  374
  427
  483
  543
  606
  673
  743
  816
  893
  973
  1,056
  1,142
  1,232
  1,326
  1,423
  1,524
  1,629
  1,738
  1,851
  1,969
  2,092
  2,220
  2,353
  2,492
  2,637
  2,788
  2,946
  3,111
  3,283
Working capital, $m
  332
  279
  321
  366
  415
  466
  521
  578
  638
  701
  767
  835
  907
  981
  1,058
  1,138
  1,222
  1,309
  1,399
  1,492
  1,590
  1,691
  1,796
  1,906
  2,021
  2,140
  2,264
  2,394
  2,529
  2,671
  2,819
Total debt, $m
  626
  696
  839
  993
  1,158
  1,333
  1,518
  1,712
  1,916
  2,130
  2,353
  2,586
  2,828
  3,080
  3,343
  3,615
  3,898
  4,192
  4,498
  4,816
  5,147
  5,491
  5,849
  6,222
  6,610
  7,015
  7,437
  7,878
  8,337
  8,818
  9,319
Total liabilities, $m
  876
  946
  1,089
  1,243
  1,408
  1,583
  1,768
  1,962
  2,166
  2,380
  2,603
  2,836
  3,078
  3,330
  3,593
  3,865
  4,148
  4,442
  4,748
  5,066
  5,397
  5,741
  6,099
  6,472
  6,860
  7,265
  7,687
  8,128
  8,587
  9,068
  9,569
Total equity, $m
  695
  702
  808
  923
  1,045
  1,175
  1,312
  1,456
  1,608
  1,766
  1,932
  2,105
  2,285
  2,472
  2,666
  2,868
  3,079
  3,297
  3,524
  3,760
  4,005
  4,261
  4,526
  4,803
  5,091
  5,392
  5,705
  6,032
  6,373
  6,730
  7,102
Total liabilities and equity, $m
  1,571
  1,648
  1,897
  2,166
  2,453
  2,758
  3,080
  3,418
  3,774
  4,146
  4,535
  4,941
  5,363
  5,802
  6,259
  6,733
  7,227
  7,739
  8,272
  8,826
  9,402
  10,002
  10,625
  11,275
  11,951
  12,657
  13,392
  14,160
  14,960
  15,798
  16,671
Debt-to-equity ratio
  0.901
  0.990
  1.040
  1.080
  1.110
  1.130
  1.160
  1.180
  1.190
  1.210
  1.220
  1.230
  1.240
  1.250
  1.250
  1.260
  1.270
  1.270
  1.280
  1.280
  1.290
  1.290
  1.290
  1.300
  1.300
  1.300
  1.300
  1.310
  1.310
  1.310
  1.310
Adjusted equity ratio
  0.382
  0.426
  0.426
  0.426
  0.426
  0.426
  0.426
  0.426
  0.426
  0.426
  0.426
  0.426
  0.426
  0.426
  0.426
  0.426
  0.426
  0.426
  0.426
  0.426
  0.426
  0.426
  0.426
  0.426
  0.426
  0.426
  0.426
  0.426
  0.426
  0.426
  0.426

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  37
  132
  156
  182
  210
  239
  270
  303
  337
  373
  410
  485
  525
  568
  612
  657
  705
  754
  805
  859
  914
  972
  1,032
  1,094
  1,159
  1,227
  1,298
  1,372
  1,449
  1,529
  1,613
Depreciation, amort., depletion, $m
  103
  81
  86
  91
  97
  103
  109
  116
  123
  130
  138
  97
  106
  114
  123
  133
  142
  152
  163
  174
  185
  197
  209
  222
  235
  249
  264
  279
  295
  311
  328
Funds from operations, $m
  51
  213
  242
  273
  307
  342
  379
  419
  460
  503
  548
  582
  631
  682
  735
  790
  847
  906
  968
  1,032
  1,099
  1,169
  1,241
  1,316
  1,395
  1,476
  1,562
  1,651
  1,743
  1,840
  1,942
Change in working capital, $m
  -105
  39
  42
  45
  48
  51
  54
  57
  60
  63
  66
  69
  71
  74
  77
  80
  83
  87
  90
  94
  97
  101
  105
  110
  114
  119
  124
  130
  135
  141
  148
Cash from operations, $m
  156
  174
  200
  228
  258
  290
  325
  361
  400
  440
  482
  514
  560
  608
  658
  710
  764
  820
  878
  939
  1,002
  1,067
  1,135
  1,206
  1,280
  1,357
  1,437
  1,521
  1,608
  1,699
  1,794
Maintenance CAPEX, $m
  0
  -28
  -32
  -37
  -43
  -48
  -54
  -61
  -67
  -74
  -82
  -89
  -97
  -106
  -114
  -123
  -133
  -142
  -152
  -163
  -174
  -185
  -197
  -209
  -222
  -235
  -249
  -264
  -279
  -295
  -311
New CAPEX, $m
  -94
  -45
  -49
  -53
  -56
  -60
  -63
  -67
  -70
  -73
  -77
  -80
  -83
  -87
  -90
  -93
  -97
  -101
  -105
  -109
  -113
  -118
  -123
  -128
  -133
  -139
  -145
  -151
  -158
  -165
  -172
Cash from investing activities, $m
  -305
  -73
  -81
  -90
  -99
  -108
  -117
  -128
  -137
  -147
  -159
  -169
  -180
  -193
  -204
  -216
  -230
  -243
  -257
  -272
  -287
  -303
  -320
  -337
  -355
  -374
  -394
  -415
  -437
  -460
  -483
Free cash flow, $m
  -149
  100
  118
  138
  159
  182
  207
  234
  262
  293
  324
  344
  379
  416
  453
  493
  534
  577
  621
  667
  715
  764
  816
  869
  925
  983
  1,043
  1,106
  1,171
  1,240
  1,311
Issuance/(repayment) of debt, $m
  83
  132
  143
  154
  165
  175
  185
  195
  204
  214
  223
  233
  242
  252
  262
  272
  283
  294
  306
  318
  331
  344
  358
  373
  388
  405
  422
  440
  460
  480
  502
Issuance/(repurchase) of shares, $m
  30
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  111
  132
  143
  154
  165
  175
  185
  195
  204
  214
  223
  233
  242
  252
  262
  272
  283
  294
  306
  318
  331
  344
  358
  373
  388
  405
  422
  440
  460
  480
  502
Total cash flow (excl. dividends), $m
  -39
  232
  262
  292
  324
  357
  392
  429
  467
  506
  547
  577
  622
  668
  716
  765
  817
  871
  927
  985
  1,045
  1,108
  1,174
  1,242
  1,313
  1,388
  1,465
  1,546
  1,631
  1,720
  1,812
Retained Cash Flow (-), $m
  17
  -99
  -106
  -114
  -122
  -130
  -137
  -144
  -152
  -159
  -166
  -173
  -180
  -187
  -195
  -202
  -210
  -218
  -227
  -236
  -245
  -255
  -266
  -277
  -288
  -300
  -313
  -327
  -341
  -356
  -372
Prev. year cash balance distribution, $m
 
  92
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  225
  155
  177
  201
  227
  255
  284
  315
  348
  382
  404
  442
  481
  521
  563
  607
  652
  700
  749
  800
  853
  908
  965
  1,025
  1,087
  1,152
  1,220
  1,290
  1,363
  1,440
Discount rate, %
 
  4.90
  5.15
  5.40
  5.67
  5.96
  6.25
  6.57
  6.89
  7.24
  7.60
  7.98
  8.38
  8.80
  9.24
  9.70
  10.19
  10.70
  11.23
  11.79
  12.38
  13.00
  13.65
  14.33
  15.05
  15.80
  16.59
  17.42
  18.29
  19.21
  20.17
PV of cash for distribution, $m
 
  215
  140
  151
  162
  170
  177
  182
  185
  185
  184
  174
  168
  161
  151
  140
  129
  116
  103
  90
  77
  65
  54
  44
  35
  28
  21
  16
  12
  8
  6
Current shareholders' claim on cash, %
  100
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0

NuVasive, Inc., a medical device company, develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery. Its products focus on applications for spine fusion surgery, including biologics used for spinal fusion process. The company’s principal product is Maximum Access Surgery, a minimally-disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, NVM5, and intraoperative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics. Its spine surgery product line offerings comprise products for the thoracolumbar and the cervical spine, which are primarily used to enable surgeons access to the spine and to perform restorative and fusion procedures in a minimally-disruptive fashion. Its biologics products include Osteocel Plus and Pro, a cellular bone matrix; Formagraft, a collagen-based synthetic bone substitute; AttraX, a synthetic bone graft material; and Propel DBM, a moldable demineralized bone matrix putty, which are used for spinal fusion or bone healing process. The company’s IOM services are used for onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. It also provides implants; and fixation products, including pedicle screws, rods, and plates. In addition, the company offers Integrated Global Alignment platform for assessing, preserving, and restoring spinal alignment; MAGEC-early onset scoliosis, a spinal bracing and distraction system; and PRECICE, a limb lengthening system. NuVasive, Inc. sells its products to hospitals, surgeons, and other customers through independent sales agents, directly-employed sales personnel, and distributors in the United States and internationally. The company was founded in 1997 and is headquartered in San Diego, California.

FINANCIAL RATIOS  of  NuVasive (NUVA)

Valuation Ratios
P/E Ratio 87.3
Price to Sales 3.4
Price to Book 4.6
Price to Tangible Book
Price to Cash Flow 20.7
Price to Free Cash Flow 52.1
Growth Rates
Sales Growth Rate 18.6%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate -13%
Cap. Spend. - 3 Yr. Gr. Rate 14.4%
Financial Strength
Quick Ratio 2
Current Ratio 0
LT Debt to Equity 81.2%
Total Debt to Equity 90.1%
Interest Coverage 6
Management Effectiveness
Return On Assets 3.1%
Ret/ On Assets - 3 Yr. Avg. 2.9%
Return On Total Capital 3.1%
Ret/ On T. Cap. - 3 Yr. Avg. 2.6%
Return On Equity 5.3%
Return On Equity - 3 Yr. Avg. 4.1%
Asset Turnover 0.7
Profitability Ratios
Gross Margin 75.1%
Gross Margin - 3 Yr. Avg. 75.7%
EBITDA Margin 18.8%
EBITDA Margin - 3 Yr. Avg. 16.9%
Operating Margin 12.8%
Oper. Margin - 3 Yr. Avg. 10.8%
Pre-Tax Margin 6.8%
Pre-Tax Margin - 3 Yr. Avg. 6.4%
Net Profit Margin 3.8%
Net Profit Margin - 3 Yr. Avg. 3.3%
Effective Tax Rate 46.2%
Eff/ Tax Rate - 3 Yr. Avg. 8.2%
Payout Ratio 0%

NUVA stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the NUVA stock intrinsic value calculation we used $962 million for the last fiscal year's total revenue generated by NuVasive. The default revenue input number comes from 2016 income statement of NuVasive. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our NUVA stock valuation model: a) initial revenue growth rate of 16.3% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.9%, whose default value for NUVA is calculated based on our internal credit rating of NuVasive, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of NuVasive.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of NUVA stock the variable cost ratio is equal to 82.8%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for NUVA stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 3.5% for NuVasive.

Corporate tax rate of 27% is the nominal tax rate for NuVasive. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the NUVA stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for NUVA are equal to 29%.

Life of production assets of 10 years is the average useful life of capital assets used in NuVasive operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for NUVA is equal to 24.9%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $695 million for NuVasive - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 50.476 million for NuVasive is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of NuVasive at the current share price and the inputted number of shares is $3.2 billion.

RELATED COMPANIES Price Int.Val. Rating
ZBH Zimmer Biomet 111.38 49.95  str.sell
GMED Globus Medical 30.11 18.91  sell
OFIX Orthofix Inter 48.00 40.63  hold
KTWO K2M Group Hold 23.45 1.59  str.sell
RTIX RTI Surgical 4.65 1.53  str.sell
SYK Stryker 144.29 191.05  buy
SPNE SeaSpine Holdi 11.67 2.48  str.sell
EXAC Exactech 29.95 3.92  str.sell

COMPANY NEWS

▶ ETFs with exposure to NuVasive, Inc. : August 14, 2017   [Aug-14-17 05:04PM  Capital Cube]
▶ Here's Why NuVasive Is Tanking Today   [Jul-28-17 12:49PM  Motley Fool]
▶ NuVasive beats 2Q profit forecasts   [12:28AM  Associated Press]
▶ Executive Changes Hit NuVasive Hard   [Jul-27-17 09:57PM  Motley Fool]
▶ ETFs with exposure to NuVasive, Inc. : May 30, 2017   [May-30-17 12:36PM  Capital Cube]
▶ ETFs with exposure to NuVasive, Inc. : May 8, 2017   [May-08-17 05:00PM  Capital Cube]
▶ ETFs with exposure to NuVasive, Inc. : April 28, 2017   [Apr-28-17 04:08PM  Capital Cube]
▶ NuVasive Straightens Up With Solid Growth   [Apr-25-17 06:28PM  Motley Fool]
▶ NuVasive beats 1Q profit forecasts   [04:46PM  Associated Press]
▶ Heres how much NuVasives 5 highest-paid executives earned   [07:20AM  American City Business Journals]
▶ NuVasive launching products to hit $100M market   [04:02PM  American City Business Journals]
▶ NuVasive Launches New Spinal Trauma Portfolio   [Apr-19-17 04:05PM  PR Newswire]
▶ NuVasive to Participate in Investor Events in March 2017   [Mar-02-17 05:34PM  PR Newswire]
▶ Masimo's Stock Is a Great Buy Right Now   [Feb-28-17 04:30PM  TheStreet.com]
▶ NuVasive Builds Momentum Going Into 2017   [07:35PM  at Motley Fool]
▶ Manufacturer hiring 200+ at Dayton-area facility   [11:56AM  at bizjournals.com]
▶ Is NuVasive, Inc. (NUVA) a Good Stock To Buy?   [Dec-01-16 10:45AM  at Insider Monkey]
▶ 2 Stocks That Quadrupled Over the Past 5 Years   [Nov-16-16 09:36AM  at Motley Fool]
▶ JobsOhio commits $1M to companies promising 395 jobs   [Nov-11-16 10:00AM  at bizjournals.com]
Stock chart of NUVA Financial statements of NUVA
Valuation of Stocks

The paper VALUATION OF STOCKS: The Quest for Intrinsic Value provides a detailed description of our valuation model and discloses the calculation algorithm.

FREE DOWNLOAD
Follow us on:   twitter   twitter   twitter   twitter

VALUATION THEORY       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2017. All rigths reserved.